Clearmind Medicine Inc.

NasdaqCM:CMND Stock Report

Market Cap: US$1.4m

Clearmind Medicine Management

Management criteria checks 2/4

Clearmind Medicine's CEO is Adi Zuloff-Shani, appointed in Jul 2021, has a tenure of 5.17 years. directly owns 0.031% of the company’s shares, worth $451.50. The average tenure of the management team and the board of directors is 3 years and 4.6 years respectively.

Key information

Adi Zuloff-Shani

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.2yrs
CEO ownership0.03%
Management average tenure3yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Analysis Article • May 21

Will Clearmind Medicine (NASDAQ:CMND) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO Compensation Analysis

How has Adi Zuloff-Shani's remuneration changed compared to Clearmind Medicine's earnings?
DateTotal CompensationSalaryCompany Earnings
Jul 31 2026n/an/a

-US$7m

Apr 30 2026n/an/a

-US$8m

Jan 31 2026n/an/a

-US$7m

Oct 31 2025n/an/a

-US$4m

Jul 31 2025n/an/a

-US$4m

Apr 30 2025n/an/a

-US$5m

Jan 31 2025n/an/a

-US$5m

Oct 31 2024US$321kUS$204k

-US$5m

Jul 31 2024n/an/a

-US$8m

Apr 30 2024n/an/a

-US$7m

Jan 31 2024n/an/a

-US$8m

Oct 31 2023US$296kUS$205k

-US$9m

Jul 31 2023n/an/a

-US$6m

Apr 30 2023n/an/a

-US$7m

Jan 31 2023n/an/a

-US$7m

Oct 31 2022n/an/a

-US$7m

Jul 31 2022n/an/a

-US$7m

Apr 30 2022n/an/a

-US$7m

Jan 31 2022n/an/a

-US$4m

Oct 31 2021US$145kUS$113k

-US$3m

Compensation vs Market: Insufficient data to establish whether Adi's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Adi's compensation has increased whilst the company is unprofitable.

CEO

Adi Zuloff-Shani (59 yo)

5.2yrs
Tenure

Dr. Adi Zuloff-Shani, Ph D., is Chief Executive Officer of Stickit Technologies Inc from July 2026. Dr. Zuloff-Shani serves as Member of Scientific Advisory Board at Nexentis Technologies Inc. (formerly kn...

Leadership Team

NamePositionTenureCompensationOwnership
Adi Zuloff-Shani
Chief Executive Officer5.2yrsno data0.031%
$ 440.9
Alan Rootenberg
Chief Financial Officer4.3yrsno data0.0048%
$ 67.0
Mark Haden
Vice President of Business Development5.2yrsno datano data
Mylene Touboul
Accounting Manager1.8yrsno datano data
Mary-Elizabeth Gifford
Chief of Global Impactless than a yearno datano data
Adi Varon
Controller1.8yrsno datano data
3.0yrs
Average Tenure
73yo
Average Age

Experienced Management: CMND's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Haden
Vice President of Business Development5.1yrsno datano data
John Krystal
Member of Scientific Advisory Board4.3yrsno datano data
Hila Kiron-Revach
Independent Chairperson2yrsUS$2.55kno data
Michael Davidson
Member of Scientific Advisory Boardno datano datano data
Wim van den Brink
Member of Scientific Advisory Board4.9yrsno datano data
Oz Adler
Independent Director5yrsno data0.013%
$ 176.6
Yehonatan Shachar
Independent Director6.4yrsno data0.0063%
$ 88.8
Gabriele Fischer
Member of Scientific Advisory Board4.9yrsno datano data
Henry Kranzler
Member of Scientific Advisory Board3.5yrsno datano data
Christian Schutz
Member of Scientific Advisory Board4.3yrsno datano data
Asaf Itzhaik
Independent Director3.8yrsUS$56.53k0.0063%
$ 88.8
Alon Friedman
Member of Scientific Advisory Boardno datano datano data
4.6yrs
Average Tenure
50.5yo
Average Age

Experienced Board: CMND's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 21:38
End of Day Share Price 2026/09/15 00:00
Earnings2026/07/31
Annual Earnings2025/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Clearmind Medicine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.